Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 28

Sort by

Sort Order Select

Journal Articles

Somatic Mutations in the Wiskott-Aldrich Syndrome Protein Family Member 3 ( WASF3 ) Are Associated with Poor Prognosis in Myeloid Malignancies

Valeria Visconte, PhD, Ali Tabarroki, MD, Li Zhang, Aaron T. Gerds, MD MS, Heesun J. Rogers, MD PhD, Velizar Shivarov, MD, PhD, John Barnard, Ramon V. Tiu, MD

Blood (2014) 124 (21): 4600.

https://doi.org/10.1182/blood.V124.21.4600.4600

Published: 2014

Journal Articles

Nitric Oxide As a Mediator of Bone Marrow Fibrosis in Patients with Myelofibrosis

Ali Tabarroki, MD, Daniel Lindner, MD PhD, Valeria Visconte, PhD, Nikolaos Papandantonakis, Jing Ai, MD PhD, Mikkael A. Sekeres, MD MS, Anjali S. Advani, MD, Matt E. Kalaycio, MD, Tracy Cinalli, RN, Kristin Colaluca, RN, Gina Rupp, John Desamito, Heesun J. Rogers, MD PhD, Ramon V. Tiu, MD

Blood (2014) 124 (21): 4587.

https://doi.org/10.1182/blood.V124.21.4587.4587

Published: 2014

Journal Articles

Impact of Non- JAK2 Molecular Mutations and Cryptic SNP Lesions in Myelofibrosis Patients Treated with Ruxolitinib

Jing Ai, MD PhD, Valeria Visconte, PhD, Ali Tabarroki, MD, Ahmad Zarzour, MD, Christopher Gerace, Karam Al-Issa, MD, Evan Hsi, Yasmine Hirbawi, Betty K. Hamilton, MD, Eric D. Hsi, MD, Heesun J. Rogers, MD PhD, Ramon V. Tiu, MD

Blood (2014) 124 (21): 3194.

https://doi.org/10.1182/blood.V124.21.3194.3194

Published: 2014

Journal Articles

Burden of Disease and Clinical Responses in Low and Intermediate-1 Risk Myelofibrosis Patients Treated with Ruxolitinib

Ahmad Zarzour, MD, Ali Tabarroki, MD, Valeria Visconte, PhD, Rokana Taftaf, MD, Heesun J. Rogers, MD PhD, Jing Ai, MD PhD, Nikolaos Papadantonakis, MD PhD, Alan E. Lichtin, Yogen Saunthararajah, MD, Brady L Stein, MDMHS, Ramon V. Tiu, MD

Blood (2014) 124 (21): 1834.

https://doi.org/10.1182/blood.V124.21.1834.1834

Published: 2014

Journal Articles

Rates of Infection in Myelofibrosis Patients Treated with Ruxolitinib

Ahmad Zarzour, MD, Ali Tabarroki, MD, Rokana Taftaf, MD, Valeria Visconte, PhD, Jing Ai, MD PhD, Betty K. Hamilton, MD, Nikolaos Papadantonakis, MD PhD, Alan E. Lichtin, Leonard J. Horwitz, MD, Anjali S. Advani, MD, Mikkael A. Sekeres, MD MS, Ramon V. Tiu, MD

Blood (2014) 124 (21): 1835.

https://doi.org/10.1182/blood.V124.21.1835.1835

Published: 2014

Journal Articles

Somatic Mutations in Splicing Factor 3b, Subunit 1 (SF3B1) Are a Useful Biomarker to Differentiate Between Clonal and Non-Clonal Causes of Sideroblastic Anemia

Valeria Visconte, PhD, Ali Tabarroki, MD, Christopher Gerace, Karam Al-Issa, MD, Eric D. Hsi, MD, Heesun J. Rogers, MD PhD, Mikkael A. Sekeres, MD MS, Bernard J. Silver, MD, Alan E. Lichtin, MD, Sudipto Mukherjee, MD MPH, Ramon V. Tiu, MD

Blood (2014) 124 (21): 5597.

https://doi.org/10.1182/blood.V124.21.5597.5597

Published: 2014

Journal Articles

Somatic Mutations of the Breast Cancer Amplified Sequence-1 (BCAS1 ), a Novel Leukemogenic Driver in Myelodysplastic Syndromes with Del(20q)

Valeria Visconte, PhD, Ali Tabarroki, MD, John Barnard, Li Zhang, Juraj Bodo, PhD, Reda Mahfouz, MD, Betty K. Hamilton, MD, Mikkael Sekeres, Anjali S. Advani, MD, Matt E. Kalaycio, MD, Yogen Saunthararajah, MD, Velizar Shivarov, MD, PhD, Shashirekha Shetty, PhD, Heesun J. Rogers, MD PhD, Ramon V. Tiu, MD

Blood (2014) 124 (21): 3250.

https://doi.org/10.1182/blood.V124.21.3250.3250

Published: 2014

Journal Articles

Triple Negative (J AK2 exon 12 /14 and MPL wild type) Myelofibrosis Have Higher Expression Of CDC25A and Greater Sensitivity To CDC25A Inhibition Compared To JAK2 Mutant Cases

Ali Tabarroki, MD, Valeria Visconte, PhD, Heesun J. Rogers, MD, PhD, Juraj Bodo, PhD, Li Zhang, Felicitas Lacbawan, Edy Hasrouni, John Barnard, Alan E. Lichtin, Daniel Lindner, Mikkael A. Sekeres, MD, MS, Ramon V. Tiu, MD

Blood (2013) 122 (21): 5259.

https://doi.org/10.1182/blood.V122.21.5259.5259

Published: 2013

Journal Articles

Spliceosome Mutations Are Frequent In Patients With Myelodysplastic Syndromes Who Failed Hypomethylating Therapy: Possible Implications Of Spliceosome Inhibitors As Alternative Treatments

Valeria Visconte, PhD, Fabiola Traina, MD, PhD, Ali Tabarroki, MD, Edy Hasrouni, Jing Ai, MD, PhD, Matt Kalaycio, MD, Anjali S. Advani, MD, Hien K. Duong, MD, Yogen Saunthararajah, M.D., John Barnard, Mikkael A. Sekeres, MD, MS, Ramon V. Tiu, MD

Blood (2013) 122 (21): 5237.

https://doi.org/10.1182/blood.V122.21.5237.5237

Published: 2013

Journal Articles

LFA-3/CD2 Pathway, Potential Target For Immunosuppressive Therapy In Aplastic Anemia: A Phase I/II Trial Of Alefacept In Patients With Relapsed/Refractory Aplastic Anemia

Ramon V. Tiu, MD, Valeria Visconte, PhD, Paul Elson, Michael J. Clemente, Ali Tabarroki, MD, Edy Hasrouni, Amy Porter, Lindsey Mooney, Manuel G. Afable, II, Ricki Englehaupt, Joy Juersivich, RN, MSc, Kathleen Cooper, RN, MSc, Mikkael A. Sekeres, MD, MS, Yogen Saunthararajah, M.D., Jaroslaw P. Maciejewski, MD, PhD

Blood (2013) 122 (21): 3711.

https://doi.org/10.1182/blood.V122.21.3711.3711

Published: 2013

Journal Articles

Poor Survival Outcomes In Myelodysplastic Syndrome Patients With Non-t(6;9) and Non-Inv(3) Balanced Chromosomal Rearrangements Are Influenced By SRSF2 Mutations

Jing Ai, MD, PhD, Valeria Visconte, PhD, Ali Tabarroki, MD, Edy Hasrouni, Betty K. Hamilton, MD, Sudipto Mukherjee, MD, PhD, MPH, Matt Kalaycio, MD, Ronald M. Sobecks, MD, Anjali S. Advani, MD, Mikkael A. Sekeres, MD, MS, Shashirekha Shetty, PhD, Ramon V. Tiu, MD

Blood (2013) 122 (21): 2809.

https://doi.org/10.1182/blood.V122.21.2809.2809

Published: 2013

Journal Articles

Modified Dose Escalation Of Ruxolitinib: A Feasible Therapeutic Approach In The Management Of Myelofibrosis

Ali Tabarroki, MD, Daniel Lindner, Valeria Visconte, PhD, Heesun J. Rogers, MD, PhD, John Desamito, Hien K. Duong, MD, Alan E. Lichtin, Anjali S. Advani, MD, Ronald M. Sobecks, MD, Tracy Cinalli, RN, Kristin Dodd, RN, Jing Ai, MD, PhD, Yogen Saunthararajah, M.D., Matt Kalaycio, MD, Brady L. Stein, MD, Mikkael A. Sekeres, MD, MS, Ramon V. Tiu, MD

Blood (2013) 122 (21): 1586.

https://doi.org/10.1182/blood.V122.21.1586.1586

Published: 2013

Journal Articles

Splicing Factor 3b Subunit 1 ( SF3B1) mediates Mitochondrial Iron Overload In Myelodysplastic Syndromes With Ring Sideroblasts By Alternative Splicing Of Mitoferrin-1 ( SLC25A37 )

Blood (2013) 122 (21): 1555.

https://doi.org/10.1182/blood.V122.21.1555.1555

Published: 2013

Journal Articles

Molecular Characterization Of Myeloid Neoplasms Harboring Isochromosome 17q Abnormality

Valeria Visconte, PhD, Ali Tabarroki, MD, Li Zhang, Edy Hasrouni, Chris Gerace, Robyn Frum, Anjali S. Advani, MD, Hien K. Duong, MD, Matt Kalaycio, MD, Yogen Saunthararajah, M.D., Mikkael A. Sekeres, MD, MS, Eric D. Hsi, MD, Shashirekha Shetty, PhD, Heesun J. Rogers, MD, PhD, Ramon V. Tiu, MD

Blood (2013) 122 (21): 2596.

https://doi.org/10.1182/blood.V122.21.2596.2596

Published: 2013

Journal Articles

Inhibition Of JAK-STAT Pathway As a Therapeutic Option For Myelofibrosis Associated Pulmonary Hypertension

Blood (2013) 122 (21): 1585.

https://doi.org/10.1182/blood.V122.21.1585.1585

Published: 2013

Journal Articles

Spliceosome Gene Mutations Are Frequently Found In JAK2 Negative Myelofibrosis and Associated With Worse Clinical Outcomes

Ali Tabarroki, MD, Valeria Visconte, PhD, Heesun J. Rogers, MD, PhD, Juraj Bodo, PhD, Li Zhang, Edy Hasrouni, John Barnard, Alan E. Lichtin, Mikkael A. Sekeres, MD, MS, Ramon V. Tiu, MD

Blood (2013) 122 (21): 4063.

https://doi.org/10.1182/blood.V122.21.4063.4063

Published: 2013

Journal Articles

BCL -2 Family Of Genes Is a Key Regulator In The Pathogenesis Of SF3B1 Mutant and Wild Type MDS With Ring Sideroblasts and Represents a Novel Drug Target In This Disease

Valeria Visconte, PhD, Reda Z Mahfouz, MD/PhD, Ali Tabarroki, MD, Edy Hasrouni, Heesun J. Rogers, MD, PhD, Yogen Saunthararajah, MD, Brian T. Hill, MD, PhD, Matt Kalaycio, MD, Mikkael A. Sekeres, MD, MS, John Barnard, Ramon V. Tiu, MD

Blood (2013) 122 (21): 263.

https://doi.org/10.1182/blood.V122.21.263.263

Published: 2013

Journal Articles

Splicing Factor 3b Subunit 1 (SF3B1) Heterozygous Mice Manifest a Hematologic Phenotype Similar To Low Risk Myelodysplastic Syndromes With Ring Sideroblasts

Valeria Visconte, PhD, Heesun J. Rogers, MD, PhD, Ali Tabarroki, MD, Li Zhang, Yvonne Parker, Edy Hasrouni, Reda Z Mahfouz, MD/PhD, Quteba Ebrahem, MD, Kyoichi Isono, Haruhiko Koseki, Anjali S. Advani, MD, Yogen Saunthararajah, M.D., Mikkael A. Sekeres, MD, MS, Daniel Lindner, John Barnard, Ramon V. Tiu, MD

Blood (2013) 122 (21): 259.

https://doi.org/10.1182/blood.V122.21.259.259

Published: 2013

Journal Articles

Newly Acquired Molecular Mutations and SNP-A Lesions Alters the Natural History of Trisomy 8 Myeloid Neoplasms

Yang Liu, BA, Paul Elson, ScD, Ali Tabarroki, MD, Valeria Visconte, PhD, Edy Hasrouni, Manoj Bupathi, MD, Betty K. Hamilton, MD, Fabiola Traina, MD, PhD, Hien K. Duong, MD, Heesun J. Rogers, MD, PhD, Yogen Saunthararajah, MD, Rami S. Komrokji, MD, Mikkael A. Sekeres, MD, MS, Ramon V Tiu, MD

Blood (2012) 120 (21): 312.

https://doi.org/10.1182/blood.V120.21.312.312

Published: 2012

Journal Articles

A Prognostic Scoring System for Unclassifiable MDS and MDS/MPN

Yang Liu, BA, Ali Tabarroki, MD, Valeria Visconte, PhD, Edy Hasrouni, Manoj Bupathi, MD, Betty K. Hamilton, MD, Fabiola Traina, MD, PhD, Hien K. Duong, MD, Heesun J. Rogers, MD, PhD, Yogen Saunthararajah, MD, Rami S. Komrokji, MD, Mikkael A. Sekeres, MD, MS, Ramon V. Tiu, MD

Blood (2012) 120 (21): 1701.

https://doi.org/10.1182/blood.V120.21.1701.1701

Published: 2012

NARROW

Somatic Mutations in the Wiskott-Aldrich Syndrome Protein Family Member 3 ( WASF3 ) Are Associated with Poor Prognosis in Myeloid Malignancies

Nitric Oxide As a Mediator of Bone Marrow Fibrosis in Patients with Myelofibrosis

Impact of Non- JAK2 Molecular Mutations and Cryptic SNP Lesions in Myelofibrosis Patients Treated with Ruxolitinib

Burden of Disease and Clinical Responses in Low and Intermediate-1 Risk Myelofibrosis Patients Treated with Ruxolitinib

Rates of Infection in Myelofibrosis Patients Treated with Ruxolitinib

Somatic Mutations in Splicing Factor 3b, Subunit 1 (SF3B1) Are a Useful Biomarker to Differentiate Between Clonal and Non-Clonal Causes of Sideroblastic Anemia

Somatic Mutations of the Breast Cancer Amplified Sequence-1 (BCAS1 ), a Novel Leukemogenic Driver in Myelodysplastic Syndromes with Del(20q)

Triple Negative (J AK2 exon 12 /14 and MPL wild type) Myelofibrosis Have Higher Expression Of CDC25A and Greater Sensitivity To CDC25A Inhibition Compared To JAK2 Mutant Cases

Spliceosome Mutations Are Frequent In Patients With Myelodysplastic Syndromes Who Failed Hypomethylating Therapy: Possible Implications Of Spliceosome Inhibitors As Alternative Treatments

LFA-3/CD2 Pathway, Potential Target For Immunosuppressive Therapy In Aplastic Anemia: A Phase I/II Trial Of Alefacept In Patients With Relapsed/Refractory Aplastic Anemia

Poor Survival Outcomes In Myelodysplastic Syndrome Patients With Non-t(6;9) and Non-Inv(3) Balanced Chromosomal Rearrangements Are Influenced By SRSF2 Mutations

Modified Dose Escalation Of Ruxolitinib: A Feasible Therapeutic Approach In The Management Of Myelofibrosis

Splicing Factor 3b Subunit 1 ( SF3B1) mediates Mitochondrial Iron Overload In Myelodysplastic Syndromes With Ring Sideroblasts By Alternative Splicing Of Mitoferrin-1 ( SLC25A37 )

Molecular Characterization Of Myeloid Neoplasms Harboring Isochromosome 17q Abnormality

Inhibition Of JAK-STAT Pathway As a Therapeutic Option For Myelofibrosis Associated Pulmonary Hypertension

Spliceosome Gene Mutations Are Frequently Found In JAK2 Negative Myelofibrosis and Associated With Worse Clinical Outcomes

BCL -2 Family Of Genes Is a Key Regulator In The Pathogenesis Of SF3B1 Mutant and Wild Type MDS With Ring Sideroblasts and Represents a Novel Drug Target In This Disease

Splicing Factor 3b Subunit 1 (SF3B1) Heterozygous Mice Manifest a Hematologic Phenotype Similar To Low Risk Myelodysplastic Syndromes With Ring Sideroblasts

Newly Acquired Molecular Mutations and SNP-A Lesions Alters the Natural History of Trisomy 8 Myeloid Neoplasms

A Prognostic Scoring System for Unclassifiable MDS and MDS/MPN

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only